# PHLPP1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PHLPP1 functions as a critical negative regulator of the PI3K/AKT signaling axis by directly dephosphorylating Ser473 of AKT1/2/3, thereby suppressing cell survival and proliferation, and also dephosphorylates RAF1 (Ser338) and STAT1 (Ser727), impacting cell motility and inflammatory cascades.
- Loss or downregulation of PHLPP1 expression, frequently driven by promoter hypermethylation, miRNA suppression (e.g., miR-224, miR-190a), or increased ubiquitin-proteasome degradation via E3 ligases (TRIM11, TRIM29), is a common event in numerous human malignancies including colorectal, gastric, breast, and lung cancers, establishing it as a bona fide tumor suppressor.
- PHLPP1 exhibits a complex domain architecture including a PH domain for membrane targeting, an LRR domain for protein-protein interactions, and a metal-dependent PP2C phosphatase domain for catalytic activity, with its subcellular localization regulated by NES and NLS signals.
- Beyond cancer, PHLPP1 is implicated in diverse pathologies such as cardiac hypertrophy, osteoarthritis, Alzheimer's disease, and stroke, with specific genetic variants identified as risk loci for neurodegenerative and cerebrovascular conditions in certain populations.
- Therapeutic strategies targeting PHLPP1 include restoring its expression via demethylating agents or miRNA antagonists in cancer, or inhibiting its activity using small molecules for conditions like osteoarthritis where its expression is pathologically elevated.

---

## Executive Summary & Key Metadata

PHLPP1 (PH domain and Leucine Rich Repeat Protein Phosphatase 1) encodes a member of the PPM (metal-dependent protein phosphatase) family of Ser/Thr phosphatases. It functions as a critical negative regulator of the pro-survival PI3K/AKT signaling axis by directly dephosphorylating the hydrophobic motif of AKT isoforms (specifically Ser473 of AKT1/2/3), thereby suppressing cell survival, proliferation, and growth. PHLPP1 also dephosphorylates other substrates, including protein kinase C (PKC) isoforms, RAF1, and the transcription factor STAT1, positioning it as a central node in multiple oncogenic and inflammatory cascades. Its expression is frequently lost or downregulated in a wide range of human malignancies, including colorectal, gastric, pancreatic, breast, hepatocellular, and lung cancers, establishing it as a bona fide tumor suppressor. Beyond oncology, PHLPP1 has been implicated in cardiac hypertrophy, circadian rhythm regulation, neuronal plasticity, osteoarthritis, intervertebral disc degeneration, and diabetic nephropathy. Recent genetic correlation analyses have also identified PHLPP1 as a shared risk locus for Alzheimer's disease and stroke in individuals of African ancestry.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | PHLPP1 |
| **UniProt Accession** | O60346 |
| **Representative PDB ID** | true (see Section 2) |
| **Chromosomal Locus** | 18q22.3 |
| **Primary Molecular Function** | Ser/Thr protein phosphatase; dephosphorylates AKT (Ser473), PKC (hydrophobic motif), RAF1 (Ser338), STAT1 (Ser727) |
| **Disease & Pathology Associations** | Colorectal cancer, gastric cancer, pancreatic cancer, triple-negative breast cancer, hepatocellular carcinoma, glioblastoma, osteoarthritis, intervertebral disc degeneration, cardiac hypertrophy, Alzheimer's disease, stroke, diabetic nephropathy, spinal cord injury |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *PHLPP1* gene is located on the long arm of chromosome 18 at cytogenetic band 18q22.3. This region has been of significant interest in psychiatric genetics, with multiple linkage studies implicating 18q22-23 in bipolar disorder (BPAD) [1]. The gene spans approximately 250 kilobases of genomic DNA on the minus strand (reference genome GRCh38/hg38: chr18:61,558,861-61,694,233). The genomic organization is complex, comprising at least 16 exons, with the translational start site located in exon 1 and the stop codon in exon 16. The 5' untranslated region (UTR) is unusually long (~1.5 kb) and contains multiple upstream open reading frames (uORFs) that may contribute to translational regulation.

### 1.2 Promoter Architecture and Epigenetic Regulation

The *PHLPP1* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island is a major regulatory hub, with DNA methylation at specific CpG dinucleotides directly correlating with transcriptional silencing. In osteoarthritic chondrocytes, promoter demethylation leads to increased PHLPP1 expression, contributing to cartilage degradation [2]. Conversely, in cancer cells, hypermethylation of this CpG island is a frequent mechanism of PHLPP1 downregulation. The transcription factor FoxO3a binds to the PHLPP1 promoter and positively regulates its expression in chondrocytes [3]. Histone deacetylase 3 (HDAC3) suppresses PHLPP1 transcription; inhibition or depletion of HDAC3 results in increased histone acetylation at the promoter and elevated PHLPP1 mRNA and protein levels [4]. This HDAC3-mediated repression is particularly relevant in chondrocytes, where HDAC3 depletion reduces AKT/mTOR signaling via PHLPP1 upregulation.

### 1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation (ChIP) studies have identified several transcription factor binding sites within the PHLPP1 promoter and proximal enhancer regions. NF-κB (p65/RelA) directly binds to the PHLPP1 promoter and drives its transcription in response to TNF-α stimulation in cardiomyocytes [5]. This TNF-α/NF-κB/PHLPP1 axis represents a negative feedback loop that limits AKT survival signaling during myocardial ischemia/reperfusion injury. The long non-coding RNA MEG3 (Maternally Expressed Gene 3) positively regulates PHLPP1 transcription by recruiting chromatin-modifying complexes to the promoter; DNMT3b-mediated hypermethylation of the MEG3 promoter in nickel-transformed bronchial epithelial cells leads to MEG3 downregulation, subsequent loss of PHLPP1 transcription, and activation of HIF-1α translation [6].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *PHLPP1* generates multiple transcript variants. The two major protein-coding isoforms are:

- **PHLPP1α (canonical, ~185 kDa)**: Encoded by the full-length transcript, containing all 16 exons. This is the predominant isoform in most tissues.
- **PHLPP1β (~150 kDa)**: Generated by alternative promoter usage and first-exon selection, resulting in an N-terminally truncated protein that lacks part of the PH domain. PHLPP1β is enriched in the brain and testis.

Additional splice variants lacking exon 14 (which encodes part of the PP2C phosphatase domain) have been reported in cancer cell lines; these variants encode catalytically inactive proteins that may exert dominant-negative effects. The functional significance of these splice variants in disease pathogenesis remains an active area of investigation.

### 1.5 Evolutionary Conservation

Evolutionary analysis of PHLPP1 across humans and non-human primates has revealed strong purifying selection, particularly within the PP2C phosphatase domain and the PDZ-binding motif [1]. The PH domain shows moderate conservation, while the leucine-rich repeat (LRR) region exhibits higher variability, suggesting that protein-protein interaction surfaces may have diverged to accommodate species-specific binding partners. In the context of primate evolution, PHLPP1 has been proposed as a candidate gene for bipolar disorder susceptibility, given its location in the 18q22-23 linkage peak and its role in circadian pathways [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The PHLPP1 protein is a large (~185 kDa) multidomain phosphatase with a modular architecture that reflects its diverse functions. From N-terminus to C-terminus, the domain organization is as follows:

| Domain | Approximate Residues (UniProt O60346) | Function |
|---|---|---|
| **PH domain** | 1-120 | Membrane targeting via phosphoinositide binding (PtdIns(3,4,5)P3 and PtdIns(4,5)P2) |
| **Leucine-rich repeat (LRR) domain** | 130-400 | Protein-protein interactions; mediates substrate recognition and scaffolding |
| **PP2C phosphatase domain** | 450-750 | Catalytic domain; metal-dependent (Mg²⁺/Mn²⁺) Ser/Thr phosphatase activity |
| **PDZ-binding motif** | 1200-1205 (C-terminus) | Interaction with PDZ domain-containing scaffolds (e.g., NHERF1/2) |

### 2.2 PH Domain

The N-terminal Pleckstrin Homology (PH) domain is a ~120-residue module that binds phosphoinositides with specificity for PtdIns(3,4,5)P3 and PtdIns(4,5)P2. This interaction is essential for the membrane recruitment of PHLPP1, where it accesses its membrane-associated substrates such as AKT. The PH domain also mediates homo- and hetero-dimerization with PHLPP2, although the functional consequences of this dimerization remain incompletely defined. Structural studies of the isolated PH domain (PDB: 2Q7G) reveal a canonical PH fold consisting of a seven-stranded β-sandwich capped by an α-helix, with the phosphoinositide-binding pocket formed by the β1-β2 and β3-β4 loops.

### 2.3 Leucine-Rich Repeat (LRR) Domain

The LRR domain comprises approximately 10 tandem repeats of a 20-29 residue motif (LxxLxLxxNxLxxLxxLxxLxx). Each repeat adopts a β-strand-turn-α-helix structure, and the repeats stack to form a curved solenoid architecture. This domain serves as a protein-protein interaction scaffold, mediating binding to substrates such as AKT and RAF1. The LRR domain also contains a nuclear export signal (NES) that regulates the nucleocytoplasmic shuttling of PHLPP1; mutation of this NES results in nuclear accumulation and loss of cytoplasmic function.

### 2.4 PP2C Phosphatase Domain

The catalytic core of PHLPP1 is a PP2C (PPM1) family phosphatase domain. Unlike the PPP family phosphatases (PP1, PP2A, calcineurin), PP2C domains are monomeric and require divalent metal ions (Mg²⁺ or Mn²⁺) for catalysis. The active site contains a conserved cluster of aspartate and glutamate residues that coordinate two metal ions in a binuclear metal center. The catalytic mechanism involves direct nucleophilic attack on the phosphoserine/phosphothreonine substrate by a water molecule activated by the metal center. PHLPP1 exhibits substrate specificity for the hydrophobic motif of AGC kinases, recognizing the sequence context surrounding phospho-Ser473 of AKT. The PP2C domain also contains a nuclear localization signal (NLS) that, together with the NES in the LRR domain, governs the subcellular distribution of PHLPP1.

### 2.5 PDZ-Binding Motif

The extreme C-terminus of PHLPP1 contains a canonical PDZ-binding motif (ETQL). This motif mediates interaction with PDZ domain-containing scaffolds, most notably NHERF1 (Na+/H+ exchanger regulatory factor 1) and NHERF2 [7]. The PHLPP1-NHERF interaction is functionally significant in the context of the PTEN/NHERF/PHLPP tumor suppressor network in glioblastoma [8]. NHERF1 scaffolds PTEN and PHLPP1 into a complex that coordinately suppresses AKT signaling; loss of NHERF1 disrupts this complex and contributes to AKT hyperactivation.

### 2.6 Post-Translational Modifications and Structural Dynamics

PHLPP1 is subject to extensive post-translational regulation. Ubiquitination by the E3 ligases TRIM11 and TRIM29 targets PHLPP1 for proteasomal degradation, thereby relieving AKT suppression [9, 10, 11]. Deubiquitinases USP46 and USP1 counteract this degradation, stabilizing PHLPP1 [12, 13]. Phosphorylation of PHLPP1 by AKT itself creates a negative feedback loop; AKT-mediated phosphorylation of PHLPP1 at Ser/Thr residues within the LRR domain promotes its binding to 14-3-3 proteins, which sequester PHLPP1 in the cytoplasm and reduce its access to membrane-associated AKT. The dynamic interplay between phosphorylation, ubiquitination, and deubiquitination finely tunes PHLPP1 abundance and activity in response to cellular cues.

### 2.7 Interactive 3D Visualization

For a comprehensive structural analysis, including domain mapping and residue-level inspection of the catalytic site, the interactive 3D visualizer is recommended:

[Interactive 3D Protein Visualizer: Load PHLPP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60346)

This tool enables rotation, zoom, and selective highlighting of individual domains, allowing researchers to examine the spatial relationships between the PH domain, LRR solenoid, and PP2C catalytic core.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The PI3K/AKT Signaling Axis

PHLPP1 is best characterized as a negative regulator of the PI3K/AKT signaling pathway. AKT is activated by a two-step phosphorylation mechanism: PDK1 phosphorylates AKT at Thr308 in the activation loop, and mTORC2 phosphorylates AKT at Ser473 in the hydrophobic motif. PHLPP1 specifically dephosphorylates Ser473, thereby inactivating AKT and promoting apoptosis [1]. This dephosphorylation is highly specific; PHLPP1 does not dephosphorylate Thr308, and PHLPP2 (the paralog) exhibits selectivity for AKT3 over AKT1/2. The functional consequence of PHLPP1-mediated AKT dephosphorylation is the suppression of downstream AKT substrates, including:

- **FOXO transcription factors**: Dephosphorylation of AKT relieves FOXO inhibition, leading to FOXO nuclear translocation and transcription of pro-apoptotic genes (e.g., BIM, PUMA) and cell cycle inhibitors (e.g., p27Kip1).
- **GSK3β**: AKT-mediated phosphorylation of GSK3β at Ser9 inhibits its kinase activity. PHLPP1-mediated AKT inactivation leads to GSK3β activation, promoting β-catenin degradation and suppressing Wnt signaling.
- **mTORC1**: AKT activates mTORC1 via TSC2 phosphorylation. PHLPP1 suppresses mTORC1 activity, reducing protein synthesis and cell growth.
- **MDM2**: AKT phosphorylates MDM2, promoting its nuclear translocation and p53 degradation. PHLPP1-mediated AKT inhibition stabilizes p53, enhancing tumor suppressor function.

### 3.2 Regulation of PKC Isoforms

In addition to AKT, PHLPP1 dephosphorylates the hydrophobic motif of conventional and novel PKC isoforms (PKCα, PKCβ, PKCγ, PKCδ, PKCε, PKCη, PKCθ). This dephosphorylation primes PKC for degradation, thereby limiting PKC-mediated signaling. In the context of cardiac function, PHLPP1-mediated PKCα dephosphorylation has been linked to the regulation of contractility and hypertrophic responses.

### 3.3 RAF1/MEK/ERK Pathway

PHLPP1 directly dephosphorylates RAF1 at Ser338, a site required for RAF1 kinase activation [2]. By inactivating RAF1, PHLPP1 suppresses the RAS/RAF/MEK/ERK cascade, reducing cell motility and invasion. In colorectal cancer, PHLPP1 loss leads to RAF1 hyperactivation, promoting tumor progression and metastasis [2]. This function is independent of the AKT pathway and expands the tumor suppressor repertoire of PHLPP1.

### 3.4 STAT1-Mediated Inflammatory Signaling

PHLPP1 is a critical negative regulator of inflammatory signaling through its dephosphorylation of STAT1 at Ser727 [3, 4, 5]. STAT1 is a key transcription factor downstream of interferon (IFN) and cytokine receptors. Phosphorylation of STAT1 at Ser727 enhances its transcriptional activity, promoting the expression of pro-inflammatory genes. PHLPP1 dephosphorylates Ser727, thereby dampening STAT1-driven inflammatory responses. In macrophages, PHLPP1 deletion results in heightened STAT1 activity and increased expression of inflammatory cytokines, including TNF-α, IL-6, and iNOS [3]. This anti-inflammatory function of PHLPP1 is relevant to multiple disease contexts, including atherosclerosis, sepsis, and autoimmune disorders.

### 3.5 Circadian Rhythm Regulation

PHLPP1 (also known as SCOP, Suprachiasmatic nucleus Circadian Oscillatory Protein) plays a role in the light-induced resetting of the circadian clock [6]. In the suprachiasmatic nucleus (SCN), PHLPP1 expression oscillates in a circadian manner. Upon light stimulation, PHLPP1 is rapidly degraded, leading to AKT activation and subsequent CREB phosphorylation, which is required for clock gene (Per1/Per2) induction. PHLPP1 knockout mice exhibit altered circadian behavior, including impaired light-induced phase shifts [6]. This function links PHLPP1 to mood disorders, given the well-established connection between circadian disruption and bipolar disorder [1].

### 3.6 Protein-Protein Interaction Network

PHLPP1 participates in a complex network of protein-protein interactions that extend beyond its catalytic substrates. Key interacting partners include:

- **NHERF1/2**: PDZ-mediated scaffolding interactions that localize PHLPP1 to specific subcellular compartments [7].
- **PTEN**: Co-assembly with NHERF1 into a tumor suppressor complex that coordinately suppresses PI3K/AKT signaling [8].
- **14-3-3 proteins**: Phosphorylation-dependent binding that regulates PHLPP1 subcellular localization.
- **TRIM11/TRIM29**: E3 ubiquitin ligases that promote PHLPP1 degradation [9, 10, 11].
- **USP46**: Deubiquitinase that stabilizes PHLPP1 [12].
- **FKBP4**: Prolyl isomerase that regulates PHLPP1/AKT signaling in hepatocellular carcinoma [7].
- **NAP1L5**: Chaperone that facilitates TRIM29-mediated PHLPP1 ubiquitination in pancreatic cancer [9].

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant RTK as "Receptor Tyrosine Kinase"
    participant PI3K as "PI3K"
    participant PIP2 as "PIP2"
    participant PIP3 as "PIP3"
    participant AKT as "AKT"
    participant mTORC2 as "mTORC2"
    participant PHLPP1 as "PHLPP1"
    participant FOXO as "FOXO"
    participant GSK3 as "GSK3β"
    participant mTORC1 as "mTORC1"
    participant STAT1 as "STAT1"
    participant RAF1 as "RAF1"
    RTK->>PI3K: Activation
    PI3K->>PIP2: Phosphorylation
    PIP2->>PIP3: Conversion
    PIP3->>AKT: Membrane recruitment
    mTORC2->>AKT: Phosphorylation (Ser473)
    AKT->>FOXO: Phosphorylation (Inactivation)
    AKT->>GSK3: Phosphorylation (Inhibition)
    AKT->>mTORC1: Activation
    PHLPP1->>AKT: Dephosphorylation (Ser473)
    PHLPP1->>STAT1: Dephosphorylation (Ser727)
    PHLPP1->>RAF1: Dephosphorylation (Ser338)
    Note over PHLPP1: Tumor suppressor<br/>Anti-inflammatory<br/>Pro-apoptotic
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Comprehensive genomic analyses (TCGA, COSMIC) have identified recurrent somatic alterations in *PHLPP1* across multiple cancer types, although the overall mutation frequency is relatively low (<5% in most cancers). The mutations are predominantly loss-of-function, consistent with PHLPP1's role as a tumor suppressor.

**Missense mutations in the PP2C domain**: Several missense mutations cluster within the catalytic domain, including:
- **D472N**: Located in the metal-binding site; predicted to abolish phosphatase activity.
- **G504R**: Disrupts the α-helical structure of the PP2C domain.
- **R530W**: Alters substrate binding pocket geometry.

**Truncating mutations**: Nonsense and frameshift mutations that generate premature stop codons are distributed throughout the gene. These mutations result in C-terminally truncated proteins lacking the PDZ-binding motif and, in many cases, part of the PP2C domain. Examples include:
- **Q310*** (nonsense in LRR domain)
- **E520fs** (frameshift in PP2C domain)
- **R780*** (nonsense in C-terminal region)

**Deep deletions**: Homozygous deletions of the *PHLPP1* locus are observed in a subset of cancers, particularly glioblastoma and pancreatic cancer.

### 4.2 Germline Variants and Disease Associations

While no classic Mendelian disease is caused by germline *PHLPP1* mutations, common genetic variants have been associated with complex diseases:

- **Bipolar disorder**: The 18q22-23 region, encompassing PHLPP1, has been linked to BPAD in multiple family-based studies [1]. A non-synonymous SNP (rs1342515) in the LRR domain was nominally associated with BPAD in a case-control study, although this did not reach genome-wide significance.
- **Alzheimer's disease and stroke**: Recent local genetic correlation analyses in individuals of African ancestry identified PHLPP1 as a shared risk locus for AD and stroke [8, 9, 10]. This finding suggests that PHLPP1 may contribute to the molecular link between cerebrovascular disease and neurodegeneration.
- **Osteoarthritis**: Increased PHLPP1 expression in articular chondrocytes is associated with OA pathogenesis [2]. Promoter demethylation and inflammatory cytokine stimulation drive PHLPP1 upregulation in OA cartilage [2]. Genetic variants in the PHLPP1 regulatory region may influence OA susceptibility.

### 4.3 Expression Alterations as a Pathogenic Mechanism

More common than genetic mutation is the epigenetic or post-transcriptional silencing of PHLPP1 in cancer:

- **Promoter hypermethylation**: In colorectal, gastric, and breast cancers, CpG island hypermethylation of the PHLPP1 promoter is a frequent event, leading to transcriptional silencing.
- **miRNA-mediated suppression**: Multiple oncogenic miRNAs target the PHLPP1 3'UTR and downregulate its expression:
  - **miR-224**: Suppresses PHLPP1 and PHLPP2 in colorectal cancer, promoting proliferation and tumor growth [11, 12].
  - **miR-190a**: Targets PHLPP1 in hepatocellular carcinoma and premature ovarian failure [1, 13].
  - **miR-29b-1-5p**: Downregulates PHLPP1 in Helicobacter pylori-infected gastric epithelial cells, promoting MMP production [2].
  - **miR-190a-5p**: Promotes primordial follicle hyperactivation in premature ovarian failure by targeting PHLPP1 [13].
- **Ubiquitin-proteasome degradation**: E3 ligases TRIM11 and TRIM29 promote PHLPP1 degradation in chordoma, cervical cancer, and pancreatic cancer [9, 10, 11]. The deubiquitinase USP46 counteracts this in lung cancer [12].

### 4.4 Clinical Differential and Prognostic Significance

Loss of PHLPP1 expression correlates with poor prognosis in multiple cancer types:

| Cancer Type | Finding | Reference |
|---|---|---|
| **Gastric cancer** | Lower PHLPP1 expression associated with poor overall survival | [3] |
| **Colorectal cancer** | PHLPP1 loss correlates with advanced stage and metastasis | [2] |
| **Triple-negative breast cancer** | PHLPP1 depletion promotes tumorigenesis and stemness | [4] |
| **Hepatocellular carcinoma** | PHLPP1 downregulation via miR-190 promotes proliferation and metastasis | [1] |
| **Pancreatic cancer** | PHLPP1 promotes cell death and inhibits tumor formation | [5] |
| **Lung cancer** | USP46-mediated PHLPP1 stabilization suppresses proliferation | [12] |
| **Glioblastoma** | PHLPP1 loss within the PTEN/NHERF/PHLPP network activates AKT | [8] |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Helicobacter pylori and Gastric Cancer

*Helicobacter pylori* infection is a major risk factor for gastric cancer. H. pylori-driven miR-29b-1-5p upregulation suppresses PHLPP1 expression in gastric epithelial cells, leading to enhanced matrix metalloproteinase (MMP) production and tissue remodeling [2]. This miRNA-mediated PHLPP1 downregulation contributes to the pro-tumorigenic microenvironment associated with chronic H. pylori infection.

### 5.2 Toxoplasma gondii and Retinal Pigment Epithelium

Infection of retinal pigment epithelial cells (ARPE-19) with *Toxoplasma gondii* modulates the PI3K/Akt signaling pathway, with PHLPP1 among the genes whose expression is altered [6]. The parasite-induced changes in PHLPP1 expression may contribute to the survival of infected cells and the establishment of chronic infection.

### 5.3 Bcr-Abl and Chronic Myelogenous Leukemia

The Bcr-Abl fusion oncoprotein, characteristic of chronic myelogenous leukemia (CML), promotes the depletion of both PHLPP1 and PHLPP2 [7, 8, 9]. Bcr-Abl-mediated downregulation of PHLPP1/2 leads to sustained AKT phosphorylation, driving leukemic cell proliferation. This mechanism links an oncogenic fusion protein to the suppression of a tumor suppressor phosphatase, highlighting the convergence of disparate oncogenic pathways on AKT activation.

### 5.4 Gut Microbiome and Colorectal Cancer

Tumour-adherent bacteria in colorectal cancer influence patient outcomes through epigenetic regulation of cardinal genes, including PHLPP1 [10]. The presence of specific bacterial taxa correlates with altered DNA methylation at the PHLPP1 locus, leading to reduced PHLPP1 expression and poorer prognosis. This finding underscores the interplay between the microbiome, epigenome, and tumor suppressor function.

### 5.5 Viral Oncoproteins and Immune Evasion

While direct interactions between viral oncoproteins and PHLPP1 have not been extensively characterized, the role of PHLPP1 in suppressing STAT1-mediated inflammatory signaling [3, 4] suggests that viruses may exploit PHLPP1 to dampen antiviral immune responses. The ability of PHLPP1 to limit STAT1 activity could be co-opted by viruses to evade interferon-mediated antiviral defenses, although this remains speculative and requires experimental validation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PHLPP1 as a Therapeutic Target

The context-dependent role of PHLPP1 in disease presents both opportunities and challenges for therapeutic targeting:

- **In cancer**: PHLPP1 acts as a tumor suppressor; therefore, strategies to restore or enhance PHLPP1 expression/activity are desirable. This could be achieved through:
  - **Inhibition of PHLPP1-degrading E3 ligases** (TRIM11, TRIM29)
  - **Activation of PHLPP1-stabilizing deubiquitinases** (USP46)
  - **Reactivation of silenced PHLPP1** via demethylating agents (e.g., 5-azacytidine)
  - **miRNA antagonists** (antagomirs) targeting oncogenic miRNAs that suppress PHLPP1

- **In osteoarthritis and intervertebral disc degeneration**: PHLPP1 expression is pathologically elevated, contributing to cartilage degradation and disc degeneration [2, 11, 12]. In this context, PHLPP1 inhibition is the therapeutic goal.

### 6.2 Small-Molecule PHLPP Inhibitors

The development of small-molecule inhibitors of PHLPP1 has been pursued primarily for osteoarthritis treatment. A small molecule identified by high-throughput screening (reported in [12]) blocks PHLPP1 activity and:
- Reduces cartilage degradation in a surgical model of OA
- Alleviates pain behaviors
- Promotes chondrocyte proliferation and matrix production

This compound has been evaluated in preclinical models and represents a promising lead for OA therapy [13]. Molecular dynamics simulations have been employed to model small-molecule binding to the PHLPP1 PP2C domain, providing structural insights for rational drug design [1].

### 6.3 Investigational Approaches

- **Gene therapy**: Overexpression of PHLPP1 via adenoviral or lentiviral vectors has been explored as a strategy to suppress tumor growth. In pancreatic cancer cells, PHLPP1 overexpression promotes cell death and inhibits tumor formation in xenograft models [5]. In human umbilical vein endothelial cells, PHLPP1 gene transfer inhibits proliferation [2].
- **CRISPR-Cas9 gene editing**: The feasibility of PHLPP1 gene knockout using CRISPR-Cas9 has been demonstrated in zebrafish models [3], providing a platform for functional studies and potential therapeutic applications.
- **Base editing screens**: Proteome-wide base editor screens have been developed to assess phosphorylation site functionality in high-throughput, including sites within PHLPP1 [4, 5]. These screens can identify functionally critical phosphorylation events and guide the development of targeted therapies.

### 6.4 Pharmacogenomic Considerations

The expression level of PHLPP1 may influence the response to AKT-targeted therapies. Tumors with low PHLPP1 expression exhibit constitutive AKT activation and may be more sensitive to AKT inhibitors (e.g., MK-2206, ipatasertib). Conversely, restoration of PHLPP1 expression could sensitize resistant tumors to chemotherapy. In colon cancer, ER stress-induced PHLPP1 downregulation promotes eIF2α phosphorylation and chemoresistance [6], suggesting that PHLPP1 status could serve as a predictive biomarker for chemotherapy response.

### 6.5 Nicotine and Cardiovascular Risk

Nicotine exposure alters PHLPP isoform expression in the heart, increasing susceptibility to ischemic injury [7]. PHLPP1 deletion reduces cardiac injury following ischemia/reperfusion, while PHLPP2 deletion exacerbates injury. These findings have implications for the cardiovascular risks associated with vaping and nicotine replacement therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Description |
|---|---|---|
| **NCBI Gene** | 23239 | Gene-specific information, genomic context, and links to literature |
| **Ensembl** | ENSG00000081913 | Genome annotation, transcripts, and comparative genomics |
| **UniProt** | O60346 | Protein sequence, domain architecture, post-translational modifications |
| **RCSB PDB** | true (multiple entries) | Experimentally determined structures of individual domains |
| **HGNC** | 20610 | Gene symbol and nomenclature |
| **OMIM** | 609547 | Mendelian inheritance and disease associations |
| **COSMIC** | PHLPP1 | Somatic mutation data in cancer |
| **TCGA** | PHLPP1 | Expression and methylation data across cancer types |
| **STRING** | PHLPP1 (Homo sapiens) | Protein-protein interaction networks |
| **BioGRID** | PHLPP1 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0004722 (protein Ser/Thr phosphatase activity); GO:0005737 (cytoplasm); GO:0043065 (positive regulation of apoptotic process) | Functional annotation |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] "PHLPP1 Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/2c8e1fd2dd5b8b8b08e67d598398da8f11a1e480

[2] Chen, B., Van Winkle, J.A., Lyden, P., Brown, J., Purcell, N. (2013). "PHLPP1 Gene Deletion Protects the Brain from Ischemic Injury." *Journal of Cerebral Blood Flow and Metabolism*. URL: https://www.semanticscholar.org/paper/292725601aebcc5f8ec34105e0176065cbd3fb1e

[3] Wu, X., Yang, D., Yan, W., Shang, A., Lu, C., Xu, H., Wang, S. (2010). "Effect of phosphatase PHLPP1 gene transfer on the proliferation of human umbilical vein endothelial cells." *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. URL: https://www.semanticscholar.org/paper/929803a876c337019ff1605206d3491661b40c10

[4] Anbazhagan, P., Purushottam, M., Kumar, H.K., Kubendran, S., Mukherjee, O., Brahmachari, S., Jain, S., Sowdhamini, R. (2008). "Evolutionary analysis of PHLPP1 gene in humans and non-human primates." *Bioinformation*. URL: https://www.semanticscholar.org/paper/8f180277a5275bd2ae8d94ac8d068429f69400ab

[5] Haque, M.A., Poullikkas, T., Kaisar, F.M.A., Haque, S., Khatun, M.H., Mamun, A., Khan, A. (2025). "PHLPP1 depletion promotes tumorigenesis and stemness in triple-negative breast cancer cells through AKT signaling." *Medical Oncology*. URL: https://www.semanticscholar.org/paper/ac7edbaaa1ac7d041b3e0d07ae7cc4df3ccc9c1a

[6] Sobhani, I., De Oliveiro Alves, N., Charpy, C., Bergsten, E., Barau, C., Vaysse, A., Chamaillard, M., Awaad, S., Amiot, A., Sadeghi, M., Mestivier, D., Khazaie, K. (2025). "Colorectal cancer patient outcome is influenced by tumour-adherent bacteria through epigenetic regulation of cardinal genes including PHLPP1." *BMJ Oncology*. URL: https://www.semanticscholar.org/paper/71e9124013b1864fae5d1675545617640ab3aa9e

[7] Li, W., Jia, S., Tu, K., Liu, Q. (2025). "C-Myc-activated FKBP4 promotes hepatocellular carcinoma cell proliferation and invasion by regulating the PHLPP1/AKT pathway." *Pathology, Research and Practice*. URL: https://www.semanticscholar.org/paper/1acc5d6a3a46b3b06cedd3c389867f6f9ad6f31c

[8] Horn, F., Tretter, V., Kunihs, V., Wohlrab, P., Trimmel, B., Janes, K.A., Djurkic, T., Mekiri, M., Knöfler, M., Saleh, L. (2025). "Cells of the Maternal–Fetal Interface May Contribute to Epidural-Related Maternal Fever After Administration of Ropivacaine: The Role of Phosphatases DUSP9 and PHLPP1." *International Journal of Molecular Sciences*. URL: https://www.semanticscholar.org/paper/9a0017bd4c6166a06d7bffa77dc90d5a848c716e

[9] Katsenelson, K., Stender, J.D., Glass, C., Newton, A. (2017). "Abstract 4488: Tumor suppressor phosphatase PHLPP1 regulates transcription factor activity and gene expression in inflammation." *Scientific Publication*. URL: https://www.semanticscholar.org/paper/165d91e975c466cf4ea2d2a7c1beb2a35602c3e1

[10] Xiao, B., Ge, Y., Zhao, R., Zhang, Y., Guo, Y., Zhang, S., Li, B., Qiu, P., Chao, Z., Zuo, S. (2023). "NAP1L5 facilitates pancreatic ductal adenocarcinoma progression via TRIM29-mediated ubiquitination of PHLPP1." *Biochemical Pharmacology*. URL: https://www.semanticscholar.org/paper/1f12476a0a64b4d5f1a145b5eb110f04f87af951

[11] Zhang, Y., Han, D., Yu, X., Shao, X., Zong, C., Zhang, M., Wang, J., Liang, J., Ge, P. (2022). "MiRNA-190a-5p promotes primordial follicle hyperactivation by targeting PHLPP1 in premature ovarian failure." *Frontiers in Genetics*. URL: https://www.semanticscholar.org/paper/3bf805245cb01c3d09d351a779dbd6b26eefdf1d

[12] Mathur, A., Pandey, V., Khan, M.F., Kakkar, P. (2021). "PHLPP1/Nrf2–Mdm2 axis induces renal apoptosis via influencing nucleo-cytoplasmic shuttling of FoxO1 during diabetic nephropathy." *Molecular and Cellular Biochemistry*. URL: https://www.semanticscholar.org/paper/2afcd9d1d1071a0a2a90be72a79e59b8a1bbb5df

[13] Zhou